While gamma-secretase and PSEN1 inhibitors are promising candidates for the treatment of T-ALL/LBL patients with NOTCH1 pathway mutations26–29, pharmacological inhibition of the JAK/STAT pathway is significantly more complex due to the presence of oncogenic mutations in multiple pathway members as well as specificity and selectivity issues affecting inhibitors against STAT proteins8–10. This evidence concerns the gene SOAT1 and acute lymphoblastic leukemia.